Results 1 to 10 of about 11,341 (256)

Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid

Nature Communications
Proteolysis targeting chimera (PROTAC) technology has received extensive attention due to its “event-driven” mechanism of action. However, existing chimera molecules tend to have higher molecular weight and higher polar surface area and exhibit lower ...
Mei-miao Zhan, Hailing Chen, Meiling He, Chunli Song, Zijun Jiao, Na Liu, Zhihong Liu, Zhanfeng Hou, Ying Chen, Zhibo Song, Yun Xing, Zigang Li, Feng Yin   +12 more
doaj   +1 more source

Schlangengift verhindert Blutgerinnsel : in den Multi-Pharmaka-Cocktails stecken raffinierte Gerinnungshemmer [PDF]

, 2010
Schlangengifte enthalten einen ganzen Arzneischrank voller hochwirksamer Stoffe, die binnen kurzer Zeit zu Schock, Lähmung oder unstillbaren Blutungen führen können. Forscher interessieren sich vor allem für Verbindungen, welche die Blutgerinnung hemmen,
Eble, Johannes Andreas
core  

Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID

Nature Communications
Here we describe ProtacID, a flexible BioID (proximity-dependent biotinylation)-based approach to identify PROTAC-proximal proteins in living cells. ProtacID analysis of VHL- and CRBN-recruiting PROTACs targeting a number of different proteins (localized
Suman Shrestha, Matthew E. R. Maitland, Laili Jing, Shili Duan, David Y. Nie, Jonathan St-Germain, Michael Kanaris, Dalia Barsyte-Lovejoy, Cheryl H. Arrowsmith, Brian Raught   +9 more
doaj   +1 more source

Boletín oficial de la provincia de León: Num. 87 (20/10/1922) [PDF]

, 1922
Copia digital. Valladolid : Junta de Castilla y León.
León (Provincia). Diputación Provincial
core   +2 more sources

Purification of protein C from canine plasma [PDF]

, 2014

core   +1 more source

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition

BMC Cancer
Purpose The human double minute 2 homolog hdm2, alias mdm2, is the main negative-regulator of the tumor suppressor p53. In that capacity, mdm2 is a promising but not yet utilized molecular target for the treatment of breast cancer, however, its ...
Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff   +5 more
doaj   +1 more source

A Structural Investigation of the Interaction between a GC-376-Based Peptidomimetic PROTAC and Its Precursor with the Viral Main Protease of Coxsackievirus B3

Biomolecules
The conservation of the main protease in viral genomes, combined with the absence of a homologous protease in humans, makes this enzyme family an ideal target for developing broad-spectrum antiviral drugs with minimized host toxicity.
Alessia De Santis, Deborah Grifagni, Andrea Orsetti, Elena Lenci, Antonio Rosato, Mariapina D’Onofrio, Andrea Trabocchi, Simone Ciofi-Baffoni, Francesca Cantini, Vito Calderone   +9 more
doaj   +1 more source

Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy

Acta Pharmaceutica Sinica B
In light of the burgeoning successes of cancer immunotherapy, glioblastoma (GBM) remains refractory due to an immunosuppressive microenvironment originating from its molecular heterogeneity.
Yeongji Jang, Jiwoong Choi, Byeongmin Park, Jung Yeon Park, Jae-Hyeon Lee, Jagyeong Goo, Dongwon Shin, Sun Hwa Kim, Yongju Kim, Hyun Kyu Song, Jooho Park, Kwangmeyung Kim, Yoosoo Yang, Man Kyu Shim   +13 more
doaj   +1 more source

In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance

Signal Transduction and Targeted Therapy
Castration-resistant prostate cancer demonstrates intrinsic or acquired resistance to second-generation androgen-targeted therapies, posing a challenge in clinical treatment.
Fei-Ya Yang, Ni-Yuan Zhang, Yang Yang, Dong Chen, Li-Yuan Wu, Wen-Kuan Wang, Hao-Xi Wang, Zhuan Wen, Ming-Ze Cai, Hao-Ze Li, Haojie Huang, Hong-Wei An, Hao Wang, Nian-Zeng Xing   +13 more
doaj   +1 more source

Editorial: The challenge of immunity evaluation and immunotherapy in gynecologic and urologic oncology

Frontiers in Immunology, 2023
Ruirong Tan, Miao Liu, Yiguan Zhang, Rui Li   +3 more
doaj   +1 more source